SCHEMBL17675281

SCHEMBL17675281

COc1cc(O)ccc1/C=C/c1cc(O)cc(O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.70
MAPT P10636 4/20 0.70
CYP1A1 P04798 7/20 0.62
CYP1B1 Q16678 6/20 0.62
TTR P02766 4/20 0.62
PTGS1 P23219 4/20 0.62
ALOX5 P09917 2/20 0.62
TYR P14679 2/20 0.62
SYNJ2 O15056 1/20 0.62
BCHE P06276 1/20 0.62
MMP2 P08253 1/20 0.62
PTPN1 P18031 1/20 0.62
PTPN22 Q9Y2R2 1/20 0.62
PTGS2 P35354 3/20 0.59
TDP1 Q9NUW8 3/20 0.56
CTSB P07858 2/20 0.56
CTSL P07711 1/20 0.56
CYP1A2 P05177 6/20 0.56
CYP3A4 P08684 4/20 0.56
CYP2C19 P33261 4/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17675282 1.00 APP (0.70) APPMAPTCYP1A1CYP1B1TTR
SCHEMBL17675463 0.90 CYP1A1 (0.67) APPMAPTCYP1A1CYP1B1TTR
SCHEMBL17675461 0.90 CYP1A1 (0.67) APPMAPTCYP1A1CYP1B1TTR
SCHEMBL1603799 0.89 APP (0.87) APPMAPTCYP1A1CYP1B1TTR
SCHEMBL1603801 0.89 APP (0.87) APPMAPTCYP1A1CYP1B1TTR
SCHEMBL5360748 0.83 APP (0.77) APPMAPTTTRALOX5TYR
SCHEMBL5360751 0.83 APP (0.77) APPMAPTTTRALOX5TYR
SCHEMBL16213550 0.82 CYP1A1 (0.67) APPMAPTCYP1A1CYP1B1PTGS1
SCHEMBL1607405 0.82 APP (1.00) APPMAPTCYP1A1CYP1B1TTR
SCHEMBL13191839 0.82 APP (1.00) APPMAPTCYP1A1CYP1B1TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4595776-A1 NUTRITIONAL COMPOSITION FOR CANCER PATIENTS AND ELDERLY SUBJECTS Pasqualetti, Giuseppe (IT) 2025-08-06 EP disclosed
US-20230145555-A1 COMPOSITION COMPRISING RESVERATROL GALENUS G.H. AG (CH) 2023-05-11 US disclosed
US-20220160649-A1 PHARMACEUTICAL COMPOSITION DOBMEYER RITA (CH) 2022-05-26 US disclosed
US-10376840-B2 Process for extraction and separation of oxyresveratrol from Artocarpus lakoocha Roxb COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2019-08-13 US disclosed
US-20170296970-A1 A PROCESS FOR EXTRACTION AND SEPARATION OF OXYRESVERATROL FROM ARTOCARPUS LAKOOCHA ROXB COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-10-19 US disclosed
EP-3204346-A1 A PROCESS FOR EXTRACTION AND SEPARATION OF OXYRESVERATROL FROM ARTOCARPUS LAKOOCHA ROXB Council of Scientific and Industrial Research (IN) 2017-08-16 EP disclosed
WO-2016056029-A1 A PROCESS FOR EXTRACTION AND SEPARATION OF OXYRESVERATROL FROM ARTOCARPUS LAKOOCHA ROXB COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160649-A1 PHARMACEUTICAL COMPOSITION FGF23, FGFR3, FGFR2 APP 2837/4885MAPT 2119/4885CYP1A1 652/4885
US-20230145555-A1 COMPOSITION COMPRISING RESVERATROL VDR, ACE2, CYP2R1 APP 1240/4885MAPT 4170/4885CYP1A1 2873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.